Brain region specific regulation of anandamide (down) and sphingosine-1-phosphate (up) in association with anxiety (AEA) and resilience (S1P) in a mouse model of chronic unpredictable mild stress.
Anxiety
Ceramides
Chronic unpredictable mild stress
Depression
Endocannabinoids
Hippocampus
Midbrain
Prefrontal cortex
Resilience
Sphingolipids
Thalamus
Journal
Pflugers Archiv : European journal of physiology
ISSN: 1432-2013
Titre abrégé: Pflugers Arch
Pays: Germany
ID NLM: 0154720
Informations de publication
Date de publication:
23 Aug 2024
23 Aug 2024
Historique:
received:
12
05
2024
accepted:
13
08
2024
revised:
12
05
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
23
8
2024
Statut:
aheadofprint
Résumé
Chronic unpredictable and unavoidable stress is associated with mental health problems such as depression and anxiety, whereas cycles of stress and stress relief strengthen resilience. It has been suggested that increased breakdown of brain endocannabinoids (eCB) promotes a feeling of adversity. To assess the impact of stress on bioactive lipid homeostasis, we analyzed eCB, sphingolipids, and ceramides in seven brain regions and plasma in a mouse model of chronic unpredictable mild stress. Chronic unpredictable mild stress (CUMS) was associated with low levels of anandamide in hippocampus and prefrontal cortex in association with indicators of anxiety (elevated plus maze). Oppositely, CUMS caused elevated levels of sphingosine-1-phosphate (S1P d18:1) and sphinganine-1-phosphate (S1P d18:0) in the midbrain and thalamus, which was associated with readouts of increased stress resilience, i.e., marble burying and struggling in the tail suspension tests. In the periphery, elevated plasma levels of ceramides revealed similarities with human major depression and suggested unfavorable effects of stress on metabolism, but plasma lipids were not associated with body weight, sucrose consumption, or behavioral features of depression or anxiety. The observed brain site-specific lipid changes suggest that the forebrain succumbs to adverse stress effects while the midbrain takes up defensive adjustments.
Identifiants
pubmed: 39177699
doi: 10.1007/s00424-024-03012-0
pii: 10.1007/s00424-024-03012-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : CRC1039 Z01
Organisme : Deutsche Forschungsgemeinschaft
ID : CRC1039 A03
Informations de copyright
© 2024. The Author(s).
Références
Altmann C, Vasic V, Hardt S, Heidler J, Haussler A, Wittig I, Schmidt MH, Tegeder I (2016) Progranulin promotes peripheral nerve regeneration and reinnervation: role of notch signaling. Mol Neurodegener 11:69. https://doi.org/10.1186/s13024-016-0132-1
doi: 10.1186/s13024-016-0132-1
pubmed: 27770818
pmcid: 5075406
Baik JH (2020) Stress and the dopaminergic reward system. Exp Mol Med 52:1879–1890. https://doi.org/10.1038/s12276-020-00532-4
doi: 10.1038/s12276-020-00532-4
pubmed: 33257725
pmcid: 8080624
Berger AL, Henricks AM, Lugo JM, Wright HR, Warrick CR, Sticht MA, Morena M, Bonilla I, Laredo SA, Craft RM, Parsons LH, Grandes PR, Hillard CJ, Hill MN, McLaughlin RJ (2018) The lateral habenula directs coping styles under conditions of stress via recruitment of the endocannabinoid system. Biol Psychiatry 84:611–623. https://doi.org/10.1016/j.biopsych.2018.04.018
doi: 10.1016/j.biopsych.2018.04.018
pubmed: 29887035
pmcid: 6162143
Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, Rahman Z, Chan K, Manners MT, Samad TA, Kennedy JD, Bingham B, Whiteside GT (2010) Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 39:148–155. https://doi.org/10.1016/j.nbd.2010.03.020
doi: 10.1016/j.nbd.2010.03.020
pubmed: 20381618
Bluett RJ, Gamble-George JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S (2014) Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry 4:e408. https://doi.org/10.1038/tp.2014.53
doi: 10.1038/tp.2014.53
pubmed: 25004388
pmcid: 4119220
Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62:1103–1110. https://doi.org/10.1016/j.biopsych.2006.12.001
doi: 10.1016/j.biopsych.2006.12.001
pubmed: 17511970
Bouter Y, Brzózka MM, Rygula R, Pahlisch F, Leweke FM, Havemann-Reinecke U, Rohleder C (2020) Chronic psychosocial stress causes increased anxiety-like behavior and alters endocannabinoid levels in the brain of C57Bl/6J mice. Cannabis Cannabinoid Res 5:51–61. https://doi.org/10.1089/can.2019.0041
doi: 10.1089/can.2019.0041
pubmed: 32322676
pmcid: 7173677
Brunkhorst-Kanaan N, Klatt-Schreiner K, Hackel J, Schroter K, Trautmann S, Hahnefeld L, Wicker S, Reif A, Thomas D, Geisslinger G, Kittel-Schneider S, Tegeder I (2019) Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder. Metabolism 95:65–76. https://doi.org/10.1016/j.metabol.2019.04.002
doi: 10.1016/j.metabol.2019.04.002
pubmed: 30954559
Brunkhorst-Kanaan N, Trautmann S, Schreiber Y, Thomas D, Kittel-Schneider S, Gurke R, Geisslinger G, Reif A, Tegeder I (2021) Sphingolipid and endocannabinoid profiles in adult attention deficit hyperactivity disorder. Biomedicines 9:9. https://doi.org/10.3390/biomedicines9091173
doi: 10.3390/biomedicines9091173
Caballero-Floran RN, Conde-Rojas I, Oviedo Chavez A, Cortes-Calleja H, Lopez-Santiago LF, Isom LL, Aceves J, Erlij D, Floran B (2016) Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent. Neuropharmacology 110:407–418. https://doi.org/10.1016/j.neuropharm.2016.08.002
doi: 10.1016/j.neuropharm.2016.08.002
pubmed: 27506997
Campos AC, Ortega Z, Palazuelos J, Fogaca MV, Aguiar DC, Diaz-Alonso J, Ortega-Gutierrez S, Vazquez-Villa H, Moreira FA, Guzman M, Galve-Roperh I, Guimaraes FS (2013) The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol 16:1407–19. https://doi.org/10.1017/S1461145712001502
doi: 10.1017/S1461145712001502
pubmed: 23298518
Cao M, Ji C, Zhou Y, Huang W, Ni W, Tong X, Wei JF (2018) Sphingosine kinase inhibitors: a patent review. Int J Mol Med 41:2450–2460. https://doi.org/10.3892/ijmm.2018.3505
doi: 10.3892/ijmm.2018.3505
pubmed: 29484372
Chen Y, Dangardt F, Friberg P (2023) Association between childhood BMI trajectories and cardiometabolic risk and mental health problems at the age of 13 years: the cohort STudy of Adolescence Resilience and Stress (STARS). Lancet Glob Health 11(Suppl 1):S3. https://doi.org/10.1016/s2214-109x(23)00088-8
doi: 10.1016/s2214-109x(23)00088-8
pubmed: 36866480
Chiu CQ, Puente N, Grandes P, Castillo PE (2010) Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J Neurosci 30:7236–7248. https://doi.org/10.1523/jneurosci.0736-10.2010
doi: 10.1523/jneurosci.0736-10.2010
pubmed: 20505090
pmcid: 2905527
Chotiwat C, Harris RB (2006) Increased anxiety-like behavior during the post-stress period in mice exposed to repeated restraint stress. Horm Behav 50:489–495. https://doi.org/10.1016/j.yhbeh.2006.06.007
doi: 10.1016/j.yhbeh.2006.06.007
pubmed: 16870191
Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706–1713. https://doi.org/10.1016/s0140-6736(07)61721-8
doi: 10.1016/s0140-6736(07)61721-8
pubmed: 18022033
Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33:91–101. https://doi.org/10.1097/WNF.0b013e3181cbf825
doi: 10.1097/WNF.0b013e3181cbf825
pubmed: 20061941
pmcid: 2859693
Cohen J, Wei Z, Phang J, Laprairie RB, Zhang Y (2020) Cannabinoids as an emerging therapy for posttraumatic stress disorder and substance use disorders. J Clin Neurophysiol 37:28–34. https://doi.org/10.1097/wnp.0000000000000612
doi: 10.1097/wnp.0000000000000612
pubmed: 31895187
Corbett BF, Luz S, Arner J, Pearson-Leary J, Sengupta A, Taylor D, Gehrman P, Ross R, Bhatnagar S (2019) Sphingosine-1-phosphate receptor 3 in the medial prefrontal cortex promotes stress resilience by reducing inflammatory processes. Nat Commun 10:3146. https://doi.org/10.1038/s41467-019-10904-8
doi: 10.1038/s41467-019-10904-8
pubmed: 31316053
pmcid: 6637233
Comings DE, Blum K (2000) Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 126:325–341. https://doi.org/10.1016/s0079-6123(00)26022-6
doi: 10.1016/s0079-6123(00)26022-6
pubmed: 11105655
Corbett B, Luz S, Sotuyo N, Pearson-Leary J, Moorthy GS, Zuppa AF, Bhatnagar S (2021) FTY720 (Fingolimod), a modulator of sphingosine-1-phosphate receptors, increases baseline hypothalamic-pituitary adrenal axis activity and alters behaviors relevant to affect and anxiety. Physiol Behav 240:113556. https://doi.org/10.1016/j.physbeh.2021.113556
doi: 10.1016/j.physbeh.2021.113556
pubmed: 34390688
Cryan JF, Mombereau C (2004) In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9:326–357. https://doi.org/10.1038/sj.mp.4001457
doi: 10.1038/sj.mp.4001457
pubmed: 14743184
de Brouwer G, Fick A, Harvey BH, Wolmarans W (2019) A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive-compulsive disorder: mapping the way forward. Cogn Affect Behav Neurosci 19:1–39. https://doi.org/10.3758/s13415-018-00653-4
doi: 10.3758/s13415-018-00653-4
pubmed: 30361863
de Brouwer G, Wolmarans W (2018) Back to basics: a methodological perspective on marble-burying behavior as a screening test for psychiatric illness. Behav Processes 157:590–600. https://doi.org/10.1016/j.beproc.2018.04.011
doi: 10.1016/j.beproc.2018.04.011
pubmed: 29694852
de Wolmarans W, Stein DJ, Harvey BH (2016) Of mice and marbles: novel perspectives on burying behavior as a screening test for psychiatric illness. Cogn Affect Behav Neurosci 16:551–560. https://doi.org/10.3758/s13415-016-0413-8
doi: 10.3758/s13415-016-0413-8
pubmed: 26920212
De Picker LJ, Morrens M, Chance SA, Boche D (2017) Microglia and brain plasticity in acute psychosis and schizophrenia illness course: a meta-review. Front Psychiatry 8:238. https://doi.org/10.3389/fpsyt.2017.00238
doi: 10.3389/fpsyt.2017.00238
pubmed: 29201010
pmcid: 5696326
De Simone R, Butera A, Armida M, Pezzola A, Boirivant M, Potenza RL, Ricceri L (2020) Beneficial effects of fingolimod on social interaction, CNS and peripheral immune response in the BTBR mouse model of autism. Neuroscience 435:22–32. https://doi.org/10.1016/j.neuroscience.2020.03.041
doi: 10.1016/j.neuroscience.2020.03.041
pubmed: 32229233
di Nuzzo L, Orlando R, Tognoli C, Di Pietro P, Bertini G, Miele J, Bucci D, Motolese M, Scaccianoce S, Caruso A, Mauro G, De Lucia C, Battaglia G, Bruno V, Fabene PF, Nicoletti F (2015) Antidepressant activity of fingolimod in mice. Pharmacol Res Perspect 3:e00135. https://doi.org/10.1002/prp2.135
doi: 10.1002/prp2.135
pubmed: 26171219
pmcid: 4492751
Di Marzo V, Despres JP (2009) CB1 antagonists for obesity–what lessons have we learned from rimonabant? Nat Rev Endocrinol 5:633–638. https://doi.org/10.1038/nrendo.2009.197
doi: 10.1038/nrendo.2009.197
pubmed: 19844251
Dixit PV, Sahu R, Mishra DK (2020) Marble-burying behavior test as a murine model of compulsive-like behavior. J Pharmacol Toxicol Methods 102:106676. https://doi.org/10.1016/j.vascn.2020.106676
doi: 10.1016/j.vascn.2020.106676
pubmed: 31954839
Dong TS, Gee GC, Beltran-Sanchez H, Wang M, Osadchiy V, Kilpatrick LA, Chen Z, Subramanyam V, Zhang Y, Guo Y, Labus JS, Naliboff B, Cole S, Zhang X, Mayer EA, Gupta A (2023) How discrimination gets under the skin: biological determinants of discrimination associated with dysregulation of the brain-gut microbiome system and psychological symptoms. Biol Psychiatry 94:203–214. https://doi.org/10.1016/j.biopsych.2022.10.011
doi: 10.1016/j.biopsych.2022.10.011
pubmed: 36754687
Dong Y, Li Y, Xiang X, Xiao ZC, Hu J, Li Y, Li H, Hu H (2023) Stress relief as a natural resilience mechanism against depression-like behaviors. Neuron 111:3789–3801. https://doi.org/10.1016/j.neuron.2023.09.004
doi: 10.1016/j.neuron.2023.09.004
pubmed: 37776853
Esch T, Stefano GB (2010) Endogenous reward mechanisms and their importance in stress reduction, exercise and the brain. Arch Med Sci 6:447–455. https://doi.org/10.5114/aoms.2010.14269
doi: 10.5114/aoms.2010.14269
pubmed: 22371784
pmcid: 3282525
Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191. https://doi.org/10.3758/bf03193146
doi: 10.3758/bf03193146
pubmed: 17695343
Friend L, Weed J, Sandoval P, Nufer T, Ostlund I, Edwards JG (2017) CB1-dependent long-term depression in ventral tegmental area GABA neurons: a novel target for marijuana. J Neurosci 37:10943–10954. https://doi.org/10.1523/jneurosci.0190-17.2017
doi: 10.1523/jneurosci.0190-17.2017
pubmed: 29038246
pmcid: 5678024
Gaetani S, Kaye WH, Cuomo V, Piomelli D (2008) Role of endocannabinoids and their analogues in obesity and eating disorders. Eat Weight Disord 13:e42-8 4959 [pii]
Garcia C, Palomo-Garo C, Gomez-Galvez Y, Fernandez-Ruiz J (2016) Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol 173:2069–2079. https://doi.org/10.1111/bph.13215
doi: 10.1111/bph.13215
pubmed: 26059564
Garcia-Gutierrez MS, Perez-Ortiz JM, Gutierrez-Adan A, Manzanares J (2010) Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol 160:1773–1784. https://doi.org/10.1111/j.1476-5381.2010.00819.x
doi: 10.1111/j.1476-5381.2010.00819.x
pubmed: 20649579
pmcid: 2936848
Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102:18620–5
doi: 10.1073/pnas.0509591102
pubmed: 16352709
pmcid: 1317988
Greene-Schloesser DM, Van der Zee EA, Sheppard DK, Castillo MR, Gregg KA, Burrow T, Foltz H, Slater M, Bult-Ito A (2011) Predictive validity of a non-induced mouse model of compulsive-like behavior. Behav Brain Res 221:55–62. https://doi.org/10.1016/j.bbr.2011.02.010
doi: 10.1016/j.bbr.2011.02.010
pubmed: 21316394
pmcid: 3097060
Gulbins E, Palmada M, Reichel M, Luth A, Bohmer C, Amato D, Muller CP, Tischbirek CH, Groemer TW, Tabatabai G, Becker KA, Tripal P, Staedtler S, Ackermann TF, van Brederode J, Alzheimer C, Weller M, Lang UE, Kleuser B, Grassme H, Kornhuber J (2013) Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med 19:934–938. https://doi.org/10.1038/nm.3214
doi: 10.1038/nm.3214
pubmed: 23770692
Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A (2013) Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 34:637–644. https://doi.org/10.1016/j.tips.2013.08.008
doi: 10.1016/j.tips.2013.08.008
pubmed: 24325918
pmcid: 4169112
Guo Y, Gan X, Zhou H, Zhou H, Pu S, Long X, Ren C, Feng T, Tang H (2020) Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activation. Life Sci 263:118582. https://doi.org/10.1016/j.lfs.2020.118582
doi: 10.1016/j.lfs.2020.118582
pubmed: 33058911
Gupta P, Taiyab A, Hussain A, Alajmi MF, Islam A, Hassan MI (2021) Targeting the sphingosine kinase/sphingosine-1-phosphate signaling axis in drug discovery for cancer therapy. Cancers (Basel) 13:8. https://doi.org/10.3390/cancers13081898
doi: 10.3390/cancers13081898
Hait NC, Wise LE, Allegood JC, O’Brien M, Avni D, Reeves TM, Knapp PE, Lu J, Luo C, Miles MF, Milstien S, Lichtman AH, Spiegel S (2014) Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci 17:971–980. https://doi.org/10.1038/nn.3728
doi: 10.1038/nn.3728
pubmed: 24859201
pmcid: 4256678
Hardt S, Heidler J, Albuquerque B, Valek L, Altmann C, Wilken-Schmitz A, Schafer MKE, Wittig I, Tegeder I (2017) Loss of synaptic zinc transport in progranulin deficient mice may contribute to progranulin-associated psychopathology and chronic pain. Biochim Biophys Acta 1863:2727–2745. https://doi.org/10.1016/j.bbadis.2017.07.014
doi: 10.1016/j.bbadis.2017.07.014
Hikida T, Yawata S, Yamaguchi T, Danjo T, Sasaoka T, Wang Y, Nakanishi S (2013) Pathway-specific modulation of nucleus accumbens in reward and aversive behavior via selective transmitter receptors. Proc Natl Acad Sci U S A 110:342–347. https://doi.org/10.1073/pnas.1220358110
doi: 10.1073/pnas.1220358110
pubmed: 23248274
Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS, Hillard CJ, Yehuda R (2013) Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 38:2952–2961. https://doi.org/10.1016/j.psyneuen.2013.08.004
doi: 10.1016/j.psyneuen.2013.08.004
pubmed: 24035186
Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ, Gorzalka BB (2008) Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 106:2322–2336. https://doi.org/10.1111/j.1471-4159.2008.05567.x
doi: 10.1111/j.1471-4159.2008.05567.x
pubmed: 18643796
pmcid: 2606621
Hill MN, Eiland L, Lee TTY, Hillard CJ, McEwen BS (2019) Early life stress alters the developmental trajectory of corticolimbic endocannabinoid signaling in male rats. Neuropharmacology 146:154–162. https://doi.org/10.1016/j.neuropharm.2018.11.036
doi: 10.1016/j.neuropharm.2018.11.036
pubmed: 30496752
Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM, Cravatt BF, Hillard CJ, Chattarji S, McEwen BS (2013) Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 18:1125–1135. https://doi.org/10.1038/mp.2012.90
doi: 10.1038/mp.2012.90
pubmed: 22776900
Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB (2005) Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30:508–515. https://doi.org/10.1038/sj.npp.1300601
doi: 10.1038/sj.npp.1300601
pubmed: 15525997
Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, Meng X, Agashivala N, Chin P, Hollander E (2016) Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: an analysis from the EPOC (Evaluate Patient OutComes) trial. J Neurol Sci 365:190–198. https://doi.org/10.1016/j.jns.2016.03.024
doi: 10.1016/j.jns.2016.03.024
pubmed: 27206905
Huston JP, Kornhuber J, Muhle C, Japtok L, Komorowski M, Mattern C, Reichel M, Gulbins E, Kleuser B, Topic B, De Souza Silva MA, Muller CP (2016) A sphingolipid mechanism for behavioral extinction. J Neurochem 137:589–603. https://doi.org/10.1111/jnc.13537
doi: 10.1111/jnc.13537
pubmed: 26788861
Isgren A, Sellgren C, Ekman CJ, Holmén-Larsson J, Blennow K, Zetterberg H, Jakobsson J, Landén M (2017) Markers of neuroinflammation and neuronal injury in bipolar disorder: relation to prospective clinical outcomes. Brain Behav Immun 65:195–201. https://doi.org/10.1016/j.bbi.2017.05.002
doi: 10.1016/j.bbi.2017.05.002
pubmed: 28483660
Jang S, Kim D, Lee Y, Moon S, Oh S (2011) Modulation of sphingosine 1-phosphate and tyrosine hydroxylase in the stress-induced anxiety. Neurochem Res 36:258–267. https://doi.org/10.1007/s11064-010-0313-1
doi: 10.1007/s11064-010-0313-1
pubmed: 21076868
Jenniches I, Ternes S, Albayram O, Otte DM, Bach K, Bindila L, Michel K, Lutz B, Bilkei-Gorzo A, Zimmer A (2016) Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. Biol Psychiatry 79:858–868. https://doi.org/10.1016/j.biopsych.2015.03.033
doi: 10.1016/j.biopsych.2015.03.033
pubmed: 25981172
Jin K, Xie L, Kim SH, Parmentier-Batteur S, Sun Y, Mao XO, Childs J, Greenberg DA (2004) Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 66:204–208. https://doi.org/10.1124/mol.66.2.204.DOI
Juhasz G, Chase D, Pegg E, Downey D, Toth ZG, Stones K, Platt H, Mekli K, Payton A, Elliott R, Anderson IM, Deakin JF (2009) CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 34:2019–2027. https://doi.org/10.1038/npp.2009.19
doi: 10.1038/npp.2009.19
pubmed: 19242408
Karbalaee M, Jameie M, Amanollahi M, TaghaviZanjani F, Parsaei M, Basti FA, Mokhtari S, Moradi K, Ardakani MK, Akhondzadeh S (2023) Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophr Res 254:92–98. https://doi.org/10.1016/j.schres.2023.02.020
doi: 10.1016/j.schres.2023.02.020
pubmed: 36805834
Kedia S, Chattarji S (2014) Marble burying as a test of the delayed anxiogenic effects of acute immobilisation stress in mice. J Neurosci Methods 233:150–154. https://doi.org/10.1016/j.jneumeth.2014.06.012
doi: 10.1016/j.jneumeth.2014.06.012
pubmed: 24932962
Kornhuber J, Muller CP, Becker KA, Reichel M, Gulbins E (2014) The ceramide system as a novel antidepressant target. Trends Pharmacol Sci 35:293–304. https://doi.org/10.1016/j.tips.2014.04.003
doi: 10.1016/j.tips.2014.04.003
pubmed: 24793541
Lammel S, Lim BK, Ran C, Huang KW, Betley MJ, Tye KM, Deisseroth K, Malenka RC (2012) Input-specific control of reward and aversion in the ventral tegmental area. Nature 491:212–217. https://doi.org/10.1038/nature11527
doi: 10.1038/nature11527
pubmed: 23064228
pmcid: 3493743
LeGates TA, Kvarta MD, Tooley JR, Francis TC, Lobo MK, Creed MC, Thompson SM (2018) Reward behaviour is regulated by the strength of hippocampus-nucleus accumbens synapses. Nature 564:258–262. https://doi.org/10.1038/s41586-018-0740-8
doi: 10.1038/s41586-018-0740-8
pubmed: 30478293
pmcid: 6292781
Li S, Sakurai K, Ohgidani M, Kato TA, Hikida T (2023) Ameliorative effects of fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice. Mol Brain 16:59. https://doi.org/10.1186/s13041-023-01047-5
doi: 10.1186/s13041-023-01047-5
pubmed: 37438826
pmcid: 10339554
Lisboa SF, Vila-Verde C, Rosa J, Uliana DL, Stern CAJ, Bertoglio LJ, Resstel LB, Guimaraes FS (2019) Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies. Psychopharmacology 236:201–226. https://doi.org/10.1007/s00213-018-5127-x
doi: 10.1007/s00213-018-5127-x
pubmed: 30604182
Loureiro M, Kramar C, Renard J, Rosen LG, Laviolette SR (2016) Cannabinoid transmission in the hippocampus activates nucleus accumbens neurons and modulates reward and aversion-related emotional salience. Biol Psychiatry 80:216–225. https://doi.org/10.1016/j.biopsych.2015.10.016
doi: 10.1016/j.biopsych.2015.10.016
pubmed: 26681496
Loureiro M, Renard J, Zunder J, Laviolette SR (2015) Hippocampal cannabinoid transmission modulates dopamine neuron activity: impact on rewarding memory formation and social interaction. Neuropsychopharmacology 40:1436–1447. https://doi.org/10.1038/npp.2014.329
doi: 10.1038/npp.2014.329
pubmed: 25510937
pmcid: 4397402
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–4
doi: 10.1038/nature00839
pubmed: 12152079
Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159:379–387. https://doi.org/10.1007/s00213-001-0946-5
doi: 10.1007/s00213-001-0946-5
pubmed: 11823890
Mateo Y, Johnson KA, Covey DP, Atwood BK, Wang HL, Zhang S, Gildish I, Cachope R, Bellocchio L, Guzmán M, Morales M, Cheer JF, Lovinger DM (2017) Endocannabinoid actions on cortical terminals orchestrate local modulation of dopamine release in the nucleus accumbens. Neuron 96:1112-1126.e5. https://doi.org/10.1016/j.neuron.2017.11.012
doi: 10.1016/j.neuron.2017.11.012
pubmed: 29216450
pmcid: 5728656
Matsuoka Y, Furuyashiki T, Yamada K, Nagai T, Bito H, Tanaka Y, Kitaoka S, Ushikubi F, Nabeshima T, Narumiya S (2005) Prostaglandin E receptor EP1 controls impulsive behavior under stress. Proc Natl Acad Sci U S A 102:16066–71
doi: 10.1073/pnas.0504908102
pubmed: 16247016
pmcid: 1276058
Mayo LM, Rabinak CA, Hill MN, Heilig M (2022) Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: a promising case of preclinical-clinical translation? Biol Psychiatry 91:262–272. https://doi.org/10.1016/j.biopsych.2021.07.019
doi: 10.1016/j.biopsych.2021.07.019
pubmed: 34598785
Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53–62. https://doi.org/10.1523/jneurosci.4503-03.2004
doi: 10.1523/jneurosci.4503-03.2004
pubmed: 14715937
pmcid: 6729571
Mikics E, Baranyi J, Haller J (2008) Rats exposed to traumatic stress bury unfamiliar objects–a novel measure of hyper-vigilance in PTSD models? Physiol Behav 94:341–348. https://doi.org/10.1016/j.physbeh.2008.01.023
doi: 10.1016/j.physbeh.2008.01.023
pubmed: 18339410
Mineur YS, Belzung C, Crusio WE (2006) Effects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice. Behav Brain Res 175:43–50
doi: 10.1016/j.bbr.2006.07.029
pubmed: 17023061
Mondelli V, Vernon AC, Turkheimer F, Dazzan P, Pariante CM (2017) Brain microglia in psychiatric disorders. Lancet Psychiatry 4:563–572. https://doi.org/10.1016/s2215-0366(17)30101-3
doi: 10.1016/s2215-0366(17)30101-3
pubmed: 28454915
Muhle C, Reichel M, Gulbins E, Kornhuber J (2013) Sphingolipids in psychiatric disorders and pain syndromes. Handb Exp Pharmacol:431–56 https://doi.org/10.1007/978-3-7091-1511-4_22
Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, Potenza MN, Bailey CR, Lin SF, Najafzadeh S, Ropchan J, Henry S, Corsi-Travali S, Carson RE, Huang Y (2013) Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 18:1034–1040. https://doi.org/10.1038/mp.2013.61
doi: 10.1038/mp.2013.61
pubmed: 23670490
pmcid: 3752332
Oleson EB, Cheer JF (2012) A brain on cannabinoids: the role of dopamine release in reward seeking. Cold Spring Harb Perspect Med 21 0.1101/cshperspect.a012229
Pan B, Hillard CJ, Liu QS (2008) D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling. J Neurosci 28:14018–14030. https://doi.org/10.1523/jneurosci.4035-08.2008
doi: 10.1523/jneurosci.4035-08.2008
pubmed: 19109485
pmcid: 2656602
Papp M, Muscat R, Willner P (1993) Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress. Psychopharmacology (Berl) 110:152–8
doi: 10.1007/BF02246965
pubmed: 7870876
Papp M, Willner P, Muscat R (1991) An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl) 104:255–9
doi: 10.1007/BF02244188
pubmed: 1876670
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMJ Open Sci 4:e100115. https://doi.org/10.1136/bmjos-2020-100115
doi: 10.1136/bmjos-2020-100115
pubmed: 34095516
pmcid: 7610906
Perona MT, Waters S, Hall FS, Sora I, Lesch KP, Murphy DL, Caron M, Uhl GR (2008) Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 19:566–574. https://doi.org/10.1097/FBP.0b013e32830cd80f
doi: 10.1097/FBP.0b013e32830cd80f
pubmed: 18690111
pmcid: 2644662
Pignatelli M, Umanah GKE, Ribeiro SP, Chen R, Karuppagounder SS, Yau HJ, Eacker S, Dawson VL, Dawson TM, Bonci A (2017) Synaptic plasticity onto dopamine neurons shapes fear learning. Neuron 93:425–440. https://doi.org/10.1016/j.neuron.2016.12.030
doi: 10.1016/j.neuron.2016.12.030
pubmed: 28103482
Raichur S, Brunner B, Bielohuby M, Hansen G, Pfenninger A, Wang B, Bruning JC, Larsen PJ, Tennagels N (2019) The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach. Mol Metab 21:36–50. https://doi.org/10.1016/j.molmet.2018.12.008
doi: 10.1016/j.molmet.2018.12.008
pubmed: 30655217
pmcid: 6407366
Reich CG, Mihalik GR, Iskander AN, Seckler JC, Weiss MS (2013) Adolescent chronic mild stress alters hippocampal CB1 receptor-mediated excitatory neurotransmission and plasticity. Neuroscience 253:444–454. https://doi.org/10.1016/j.neuroscience.2013.08.066
doi: 10.1016/j.neuroscience.2013.08.066
pubmed: 24035826
Romano-López A, Méndez-Díaz M, García FG, Regalado-Santiago C, Ruiz-Contreras AE, Prospéro-García O (2016) Maternal separation and early stress cause long-lasting effects on dopaminergic and endocannabinergic systems and alters dendritic morphology in the nucleus accumbens and frontal cortex in rats. Dev Neurobiol 76:819–831. https://doi.org/10.1002/dneu.22361
doi: 10.1002/dneu.22361
pubmed: 26539755
Sbarski B, Akirav I (2020) Cannabinoids as therapeutics for PTSD. Pharmacol Ther 211:107551. https://doi.org/10.1016/j.pharmthera.2020.107551
doi: 10.1016/j.pharmthera.2020.107551
pubmed: 32311373
Schwalm S, Beyer S, Hafizi R, Trautmann S, Geisslinger G, Adams DR, Pyne S, Pyne N, Schaefer L, Huwiler A, Pfeilschifter J (2021) Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis. Cell Signal 79:109881. https://doi.org/10.1016/j.cellsig.2020.109881
doi: 10.1016/j.cellsig.2020.109881
pubmed: 33301900
Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S, Meyer JH (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiat 72:268–275. https://doi.org/10.1001/jamapsychiatry.2014.2427
doi: 10.1001/jamapsychiatry.2014.2427
Setsu T, Hamada Y, Oikawa D, Mori T, Ishiuji Y, Sato D, Narita M, Miyazaki S, Furuta E, Suda Y, Sakai H, Ochiya T, Tezuka H, Iseki M, Inada E, Yamanaka A, Kuzumaki N, Narita M (2021) Direct evidence that the brain reward system is involved in the control of scratching behaviors induced by acute and chronic itch. Biochem Biophys Res Commun 534:624–631. https://doi.org/10.1016/j.bbrc.2020.11.030
doi: 10.1016/j.bbrc.2020.11.030
pubmed: 33220930
Steiner H, Bonner TI, Zimmer AM, Kitai ST, Zimmer A (1999) Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc Natl Acad Sci U S A 96:5786–90
doi: 10.1073/pnas.96.10.5786
pubmed: 10318962
pmcid: 21938
Steptoe A, Deaton A, Stone AA (2015) Subjective wellbeing, health, and ageing. Lancet 385:640–648. https://doi.org/10.1016/s0140-6736(13)61489-0
doi: 10.1016/s0140-6736(13)61489-0
pubmed: 25468152
Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85:367–70
doi: 10.1007/BF00428203
pubmed: 3923523
Tellez LA, Medina S, Han W, Ferreira JG, Licona-Limon P, Ren X, Lam TT, Schwartz GJ, de Araujo IE (2013) A gut lipid messenger links excess dietary fat to dopamine deficiency. Science 341:800–802. https://doi.org/10.1126/science.1239275
doi: 10.1126/science.1239275
pubmed: 23950538
Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R (2009) Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology 204:361–373. https://doi.org/10.1007/s00213-009-1466-y
doi: 10.1007/s00213-009-1466-y
pubmed: 19189082
pmcid: 2899706
Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL (2010) Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376:517–523. https://doi.org/10.1016/s0140-6736(10)60935-x
doi: 10.1016/s0140-6736(10)60935-x
pubmed: 20709233
van Zessen R, Phillips JL, Budygin EA, Stuber GD (2012) Activation of VTA GABA neurons disrupts reward consumption. Neuron 73:1184–1194. https://doi.org/10.1016/j.neuron.2012.02.016
doi: 10.1016/j.neuron.2012.02.016
pubmed: 22445345
pmcid: 3314244
Ventura R, Coccurello R, Andolina D, Latagliata EC, Zanettini C, Lampis V, Battaglia M, D’Amato FR, Moles A (2013) Postnatal aversive experience impairs sensitivity to natural rewards and increases susceptibility to negative events in adult life. Cereb Cortex 23:1606–1617. https://doi.org/10.1093/cercor/bhs145
doi: 10.1093/cercor/bhs145
pubmed: 22669969
Vogel A, Wilken-Schmitz A, Hummel R, Lang M, Gurke R, Schreiber Y, Schäfer MKE, Tegeder I (2020) Low brain endocannabinoids associated with persistent non-goal directed nighttime hyperactivity after traumatic brain injury in mice. Sci Rep 10:14929. https://doi.org/10.1038/s41598-020-71879-x
doi: 10.1038/s41598-020-71879-x
pubmed: 32913220
pmcid: 7483739
Wang W, Sun D, Pan B, Roberts CJ, Sun X, Hillard CJ, Liu QS (2010) Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress. Neuropsychopharmacology 35:2249–2261. https://doi.org/10.1038/npp.2010.99
doi: 10.1038/npp.2010.99
pubmed: 20664582
pmcid: 3055309
Wang DV, Tsien JZ (2011) Convergent processing of both positive and negative motivational signals by the VTA dopamine neuronal populations. PLoS ONE 6:e17047. https://doi.org/10.1371/journal.pone.0017047
doi: 10.1371/journal.pone.0017047
pubmed: 21347237
pmcid: 3039659
Wenzel JM, Cheer JF (2014) Endocannabinoid-dependent modulation of phasic dopamine signaling encodes external and internal reward-predictive cues. Front Psychiatry 5:118. https://doi.org/10.3389/fpsyt.2014.00118
doi: 10.3389/fpsyt.2014.00118
pubmed: 25225488
pmcid: 4150350
Wilker S, Pfeiffer A, Elbert T, Ovuga E, Karabatsiakis A, Krumbholz A, Thieme D, Schelling G, Kolassa IT (2016) Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Psychoneuroendocrinology 67:198–206. https://doi.org/10.1016/j.psyneuen.2016.02.010
doi: 10.1016/j.psyneuen.2016.02.010
pubmed: 26923850
Willner P, Lappas S, Cheeta S, Muscat R (1994) Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl) 115:454–62
doi: 10.1007/BF02245568
pubmed: 7871089
Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987) Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93:358–64
doi: 10.1007/BF00187257
pubmed: 3124165
Witkin JM (2008) Animal models of obsessive-compulsive disorder. Curr Protoc Neurosci Chapter 9:Unit 9.30 https://doi.org/10.1002/0471142301.ns0930s45
Yalcin I, Bohren Y, Waltisperger E, Sage-Ciocca D, Yin JC, Freund-Mercier MJ, Barrot M (2011) A time-dependent history of mood disorders in a murine model of neuropathic pain. Biol Psychiatry 70:946–953. https://doi.org/10.1016/j.biopsych.2011.07.017
doi: 10.1016/j.biopsych.2011.07.017
pubmed: 21890110
Yi X, Tang X, Li T, Chen L, He H, Wu X, Xiang C, Cao M, Wang Z, Wang Y, Wang Y, Huang X (2023) Therapeutic potential of the sphingosine kinase 1 inhibitor, PF-543. Biomed Pharmacother 163:114401. https://doi.org/10.1016/j.biopha.2023.114401
doi: 10.1016/j.biopha.2023.114401
pubmed: 37167721
Yu X, Qi X, Wei L, Zhao L, Deng W, Guo W, Wang Q, Ma X, Hu X, Ni P, Li T (2023) Fingolimod ameliorates schizophrenia-like cognitive impairments induced by phencyclidine in male rats. Br J Pharmacol 180:161–173. https://doi.org/10.1111/bph.15954
doi: 10.1111/bph.15954
pubmed: 36106568
Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96:5780–5
doi: 10.1073/pnas.96.10.5780
pubmed: 10318961
pmcid: 21937